# Evaluation of Blood Pressure Reduction, Safety, and Tolerability of Canagliflozin in Patients With Hypertension and Type 2 Diabetes Mellitus on Stable Doses of Anti-hyperglycemic and Anti-hypertensive Agents

Study · id `cardio:ct-nct01939496` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01939496](<https://clinicaltrials.gov/study/NCT01939496>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01939496

Browse, organ or system: Blood vessels; Metabolism  
Browse, condition area: High blood pressure; Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 171 participants.

## Technical summary

Registry record NCT01939496. Randomized; quadruple masking; primary purpose treatment. Start 2013-10 (registry gives no type); primary completion 2015-04 (actual). Results posted on 2016-04-06.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 171 participants (enrolled count; ClinicalTrials.gov record NCT01939496, source copy `cardio:ctgov-nct01939496-2017-03-03`, retrieved 2026-10-26)
- Start date: 2013-10 (registry gives no type) (ClinicalTrials.gov record NCT01939496, source copy `cardio:ctgov-nct01939496-2017-03-03`, retrieved 2026-10-26)
- Primary completion: 2015-04 (actual) (ClinicalTrials.gov record NCT01939496, source copy `cardio:ctgov-nct01939496-2017-03-03`, retrieved 2026-10-26)
- Completion: 2015-04 (actual) (ClinicalTrials.gov record NCT01939496, source copy `cardio:ctgov-nct01939496-2017-03-03`, retrieved 2026-10-26)
- Results first posted: 2016-04-06 (ClinicalTrials.gov record NCT01939496, source copy `cardio:ctgov-nct01939496-2017-03-03`, retrieved 2026-10-26)
- Countries: United States; Puerto Rico (ClinicalTrials.gov record NCT01939496, source copy `cardio:ctgov-nct01939496-2017-03-03`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01939496-2017-03-03`, retrieved 2026-10-26)

## The registry's words

- Brief title: Evaluation of Blood Pressure Reduction, Safety, and Tolerability of Canagliflozin in Patients With Hypertension and Type 2 Diabetes Mellitus on Stable Doses of Anti-hyperglycemic and Anti-hypertensive Agents
- Condition: Diabetes Mellitus, Type 2
- Condition: Hypertension
- Intervention (Drug): Canagliflozin
- Intervention (Drug): Placebo
- Lead sponsor: Janssen Scientific Affairs, LLC
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry lists this organization as the lead sponsor: Janssen Scientific Affairs, LLC (`cardio:org-janssen-scientific-affairs-llc`)

## Provenance

Content hash: bc75cb672958cd6dbb554501368ca601b5b5c722b42731b01e81d2622d2e8f80
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
